Pharmacology & Pharmacy, 2016, 7, 358-367 Published Online August 2016 in SciRes. http://www.scirp.org/journal/pp http://dx.doi.org/10.4236/pp.2016.78044

How to cite this paper: Park, Y.-S., Kim, S.-H., Kim, S.-Y., Koh, G.-M., Suh, J.-H. and Kang, J.-S. (2016) Topical Application of Cudrania tricuspidata Stem Extract Inhibits Atopic Dermatitis-Like Skin Lesions in an NC/Nga Mouse Model: An Experimen-tal Animal Study. Pharmacology & Pharmacy, 7, 358-367. http://dx.doi.org/10.4236/pp.2016.78044

Topical Application of Cudrania tricuspidata Stem Extract Inhibits Atopic Dermatitis-Like Skin Lesions in an NC/Nga Mouse Model: An Experimental Animal Study Yoo-Sin Park1,2,3, Shin-Hee Kim4,5, Sang-Yeon Kim4,6, Gae-Myoung Koh4, Ju-Hwan Suh7, Ju-Seop Kang1,4,5,6,8* 1Division of Molecular Therapeutics Development, Hanyang Biomedical Research Institute, Hanyang University, Seoul, Republic of Korea 2Department of Clinical Nutrition, Shintong Rehabilitation Clinic, Yongin, Republic of Korea 3Department of Food & Nutrition, Hanyang Women’s University, Seoul, Republic of Korea 4Department of Pharmacology, College of Medicine, Hanyang University, Seoul, Republic of Korea 5Institute of Medical Science, Hanyang University, Seoul, Republic of Korea 6Department of New Drug Development, College of Medicine, Hanyang University, Seoul, Republic of Korea 7Department of Biology, Johns Hopkins University, Maryland, USA 8Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Republic of Korea

Received 2 August 2016; accepted 28 August 2016; published 31 August 2016

Copyright © 2016 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/

Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by elevated immu-noglobulin E (IgE), mast cell infiltration and skin lesions including pruritus, erythema and eczema. Cudrania tricuspidata extracts have been clinically administered for a long time in the East Asia including Korean and China as a home-remedy to diminish the inflammation of gastritis and hepa-titis. To examine whether it works on AD or not, an AD-like animal model was experimented in this study. AD was induced by applying Dermatophagoides farinae (D. farinae) extract to the backs of 9-week old NC/Nga mice for 21 days. Following this, an ethanol extract of C. tricuspidata stems (EECT) was applied topically for 14 days to the sensitized skin, while distilled water was used as a control (EECT0 mice). Anti-AD effects of EECT were evaluated using scores for AD-like skin lesions, serum IgE levels and mast cell counts in the skin dermal layers to assess inflammation. Topically applied ethanol extract of Cudrania tricuspidata stems (EECT 7.5, 25 and 75 mg/mL) markedly reduced AD-like skin lesions after 4 days (by 30.1%, 31.4% and 38.5%, respectively) and also after

*Corresponding author.

Y.-S. Park et al.

359

14 days (by 63.6%, 66.1% and 49.6%, respectively), while distilled water improved AD by 17.8% and 38.7%, respectively (p < 0.05). Serum IgE production was reduced in the EECT7.5, EECT25 and EECT75 groups after 4 days (by 57.6%, 65.9% and 59.3%, respectively) and after 14 days of the treatment (by 82.0%, 79.6% and 75.3%, respectively), while distilled water decreased it by 38.8% and 62.3% (p = 0.0001 and p = 0.0001, respectively). Mast cell counts increased after sensitization by D. farinae extract (p = 0.003) and EECT attenuated the mast cell overproduction, and reduced mast cell degranulation markedly. Attenuation was most obvious in the early stage of EECT treat-ment when the AD was most acute.

Keywords Atopic Dermatitis, Cudrania tricuspidata Stem, Dermatophagoides farina, Immunoglobulin E (IgE), NC/Nga Mouse

1. Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease accompanied by representative symptoms such as itch, erythema, excoriation, edema, dryness and scaling [1]. It is very prevalent in infants and nowadays has also spread to adolescents and adults. Its causes are not fully understood, but inflammatory dysregulation of the im-mune system of the skin and mucous membranes in response to allergens is probably involved. This immuno-logic disturbance is reflected in elevated serum immunoglobulin E (IgE) resulting from increased inflammatory cell infiltration into the skin, and is dominated by type2 helper T-cells [2]. Accordingly, AD is characterized by histopathologic skin changes and dermatitis lesions of the face, neck, head, arms, knees and elbows. Therefore, sensory evaluation of the disturbance caused by such skin lesions or determination of IgE levels is used to diag-nose or evaluate AD [3].

We examined a natural material with anti-inflammatory effects as a new drug candidate for AD treatment. The selected natural material was extract of Cudrania tricuspidata (C. tricuspidata), a kind of mulberry tree which is native to East Asian countries such as Korea, China and Japan [4]-[7], and occurs mainly in the southern area of South Korea [5]. Extracts of the fruit, leaves, root-bark and stems of C. tricuspidata have been traditionally used for hepato-protection [8]-[10], and as anti-hypertension [11], anti-diabetes [12] [13], anti-allergy [14] and anti- oxidation [15]-[17] treatments in Korea. Well-known physiologically active compounds of C. tricuspidata are isoflavones and flavonoids from the fruits [18], gerontoxanthone, cudraflavone B, gericudranin, cudraxanthones, isocudraxanthones, some flavanones and macluraxanthone from the roots [9] [19], kaempferol and kaempferol- D-glucopyranoside from the leaves [20], and kaempferide-D-glucopyranoside and naringenin-D-glucopyrano- side from the stems [21]. However, the anti-AD effects of C. tricuspidata have not been studied except for a recent report using fruit extract [22]. Therefore, we examined the therapeutic effect of ethanol extract of C. tricuspidata stems (EECT) on AD symptoms when administered topically in an NC/Nga mice AD model induced by Derma- tophagoides farinae (D. farinae) extract.

2. Materials and Methods 2.1. Preparation of the EECT Dried stems of C. tricuspidata were finely powdered, and biologically active compounds were extracted with 95% ethanol (1:10, v/v) for 24 h, in a 60˚C water bath, then filtered through filter paper (ADVANTEC No.2, 150 mm) under vacuum. The filtrate was concentrated by evaporation at 45˚C, then deep-frozen at −70˚C after reconstitu-tion in 70% ethanol in a concentration range of 100 - 200 mg/mL. The frozen filtrate was diluted appropriately after thawing to room temperature. Three concentrations of the ethanol extract (EECT) namely 7.5, 25 and 75 mg/mL, were prepared by diluting with distilled water, and tested topically.

2.2. Induction of AD-Like Skin Lesions in an NC/Nga Mouse Model Twenty-eight NC/Nga mice (9 week-old, male) were purchased from Central Exp. Animals Co. Ltd. (South Ko-

Y.-S. Park et al.

360

rea), and all animal procedures were approved by the Institutional Animal Care and Use Committee of Hanyang University (No: HY-IACUC-10-062). After one-week of adaptation, the mice were anesthetized with ether and their heads, necks and shoulders shaved with razors and waxing cream. Then twenty-four of the mice were topi-cally administered 100mg of D. farinae (house mite) extract-ointment (Biostar AD ointment, Japan) on their shaved skin regions six times over 21 days to induce AD-like skin lesions [23]. 4% SDS solution was used to brush their shaved skin instead of waxing cream after the first administration of house mite extract [23]. On the 21st day, the severity of the AD-like skin lesions was evaluated. Eight mice died during the AD induction period during waxing and sensitization, and the remaining twenty mice were divided into five groups.

2.3. Treatment on the AD-Like Skin Lesions with EECT On the 21st day EECT was administered to three experimental groups of 4 mice receiving 7.5 mg/mL, 25 mg/ml and 75 mg/mL EECT, respectively, for 14 days. The EECT was topically applied with a small flat brush once a day on all the treated skin areas. Distilled water was administered to the control group (EECT0, n = 4) in the same manner, while the “normal” group (normal, n = 4) received no treatment.

2.4. Changes of AD-Like Skin Lesions The changes of the AD-like skin lesions were assessed visually by two trained investigators on the 21st day of sensitization, and after the 4th, 10th and 14th day of EECT treatment. The severity was scored as the sum of the AD scores for each category, namely itch, edema, erythema/hemorrhage, excoriation/erosion and dryness/ scaling, graded as 0 (no symptoms), 1 (mild symptoms), 2 (moderate symptoms) and 3 (severe symptoms) [24]- [26]. Then the AD score for each group was converted to “AD reduction (%)” calculated from the equation {(AD score at baseline − AD score at the 4th, 10th or 14th day of EECT treatment)/AD score at baseline} × 100.

2.5. Changes of Inflammation Measured from Serum IgE Levels Orbit blood was collected under ether anesthesia on the final day of AD induction, then on the 4th, 10th and 14th days of treatment. Sera were deep-frozen at −70˚C after centrifugation of blood at 3000 rpm, 4˚C for 20 min. Serum IgE levels were determined using a Mouse IgE ELISA Assay kit (XpressBio Life Science Prod-ucts, Catalog No: 595-700, Express Biotech International, Thurmont, USA) at 450 nm expressed as {(serum IgE level at baseline − serum IgE level on the 4th, 10th or 14th day of EECT treatment)/serum IgE level at baseline} × 100.

2.6. Histopathologic Evaluation After the 14 days of EECT treatment, all the mice were killed under ether anesthesia after evaluation of the AD-like skin lesions and orbit blood sampling, and the skin was removed from the affected regions of the ani-mals’ heads, necks and shoulders. The skin was fixed with 10% formaldehyde, embedded in paraffin, and thin sections were made. The sections were stained with toluidine blue O, and microscopic examination was carried out at ×200; the total numbers of mast cells including granulated and degranulated forms were counted at five sites (400 μm2) chosen at random in each skin sample [26]-[28].

2.7. Statistical Evaluation The measurements on the five groups were compared by one-way ANOVA and by post-hoc Duncan or Scheffe test at p < 0.05 using SPSS ver. 21.0. Eight mice died due to excess anesthesia during the AD induc-tion period.

3. Results 3.1. The Therapeutic Effects of EECT on AD-Like Skin Lesions The changes of AD-like skin lesions from the baseline at the end of AD induction to the 14 days after the EECT treatment are presented in Figure 1(a). AD-like skin lesions were reduced by the 14-day EECT treatment

Y.-S. Park et al.

361

(Figure 1(b)), and significant reductions compared to EECT 0 were noted after 4 days of treatment only with 25 and 75 mg/mL EECT (p = 0.0001), even though EECT 7.5, 25 and 75 mg/mL were equally effective (30.1% ± 2.4% vs. 31.4% ± 6.7% vs. 38.5% ± 2.7%). The extent of the AD reduction increased by 14 days of EECT treatment (63.6% ± 9.8% vs. 66.1% ± 6.3% vs. 49.6% ± 12.9%, respectively), and to a lesser extent (from 17.8%

Figure 1. The changes of AD-like skin lesions from baseline at the end of AD induction. (a) The AD reductions (%) in each group were compared with the EECT0 group by one-way ANOVA with Duncan’s posthoc test. † (p < 0.001); (b) Represent-ative photographs of AD-like skin lesions before and after EECT treatment. EECT = ethanol extract of C. tricuspidata stems; Normal = no AD induction and no EECT treatment; EECT0 = AD induction and distilled water treatement (control); EECT7.5 = AD induction and 7.5 mg/mL EECT treatment; EECT25 = AD induction and 25 mg/mL EECT treatment; EECT75 = AD induction and 75 mg/mL EECT treatment (mean ± SEM, n = 4).

Y.-S. Park et al.

362

± 5.4% (4 days) to 38.7% ± 9.9% (14 days)) in the EECT0 group. In spite of the higher AD reduction in the EECT-treated groups, no significant differences were found between the EECT0 and EECT-treated groups after 14 days of EECT treatment. Importantly, the AD-like skin lesions were improved most when the mice were treated with EECT 25 mg/mL for 14 days, and the therapeutic effect of EECT 25 mg/mL was significantly greater than that seen in the EECT0 group in the early stage of treatment.

3.2. Effects of EECT on Serum IgE Levels The changes of serum IgE levels during the EECT treatment for 14 days are presented in Figure 2. Serum IgE levels were dramatically reduced by EECT throughout the 14-day treatment, and significant reductions (%) were observed at each time point at 4 days (57.6% ± 7.7% vs. 65.9% ± 5.2% vs. 59.3% ± 6.7%), 10 days (74.9% ± 5.1% vs. 80.4% ± 4.6% vs. 74.2% ± 6.7%) and 14 days (82.0% ± 3.7% vs. 79.6% ± 6.0% vs. 75.3% ± 7.4%) of EECT treatment (7.5 vs. 25 vs. 75 mg/mL) compared to the EECT 0 group (38.8% ± 6.9%, 53.9% ± 10.2%, and 62.3% ± 7.5%; p = 0.0001, p = 0.0001, and p = 0.0001, respectively). EECT 7.5 and 25 mg/mL were the most effective doses.

3.3. Effects on Mast Cell Counts Stained with Toluidine Blue O Numbers of mast cells (both granulated and degranulated forms) in the skin dermis layers stained with toluidine BlueO were examined by optical microscopy (200×) (Figure 3) as described in Materials and Methods. Total mast cell counts were significantly increased after sensitization by D. farinae extract when compared to normal mice (p = 0.003; (Figure 4): normal (153.0 ± 7.5) vs. EECT0 (659.0 ± 129.3), EECT7.5 (469.5 ± 39.2), EECT25 (541.0 ± 80.2) and EECT75 (544.0 ± 48.8)). However, total mast cell counts tended to increase less in

Figure 2. The changes of serum IgE from baseline at the end of AD induction. The IgE reduc-tions (%) in each group were compared with the EECT0 group by one-way ANOVA with Dun-can’s posthoc test ‡ (p < 0.0001). EECT = ethanol extract of C. tricuspidata stems; Normal = no AD induction and no EECT treatment; EECT0 = AD induction and distilled water treatement (control); EECT7.5 = AD induction and 7.5 mg/mL EECT treatment; EECT25 = AD induction and 25 mg/mL EECT treatment; EECT75 = AD induction and 75 mg/mL EECT treatment (mean ± SEM, n = 4).

Y.-S. Park et al.

363

Figure 3. The representative optical microscopic images (200×) of mast cells. Granulated (◁) and degranulated (◀) mast cells in the skin dermis stained with toluidine Blue O after 14 days of EECT treatment. Other details are the same as in Fig-ure 1 and Figure 2.

Figure 4. Mast cell counts at five sites (400 μm2) chosen at random in the skin samples. Mean mast cell counts in each group were compared with the EECT0 group by one-way ANOVA with Duncan’s posthoc test, and statistical differences among the groups were presented as different alphabetical scripts on the bar charts of each group at p < 0.05 (mean ± SEM, n = 4). Other details are the same as in Figure 1 and Figure 2. the EECT-treated groups, especially the EECT7.5 group, than in the distilled water-treated (EECT0) group. This tendency was particularly evident in the skin dermis of heads and necks. The granulated and degranulated forms of mast cells were also counted separately, and only the latter increased significantly after AD induction (p = 0.0001; normal (45.0 ± 8.1) vs. EECT0 (484.8 ± 60.8)) while degranulated mast cells increased significantly less when treated with EECT (EECT7.5 (315.0 ± 36.6), EECT25 (289.0 ± 19.6) and EECT75 (362.0 ± 18.2)) than

Y.-S. Park et al.

364

with distilled water (Figure 4). The topical use of EECT 7.5, 25 and 75 mg/mL on the AD-like skin lesions for 14 days was effective in reducing numbers of degranulated mast cells even though they did not reach the num-bers in the normal group (p = 0.0001).

4. Discussion In the current study, topically applied EECT had a significant effect on the severity of AD-like skin lesions, se-rum IgE levels and on mast cell counts in the skin dermis. The anti-AD effects of EECT were detectible when EECT 7.5, 25 and 75 mg/mL were applied topically for 14 days to the mice (Figure 1), and these therapeutic effects are presumed to be due to diminution of systemic inflammatory reactions (Figure 2) and histopathologi-cal changes (Figure 3 and Figure 4). Natural recovery from the AD-like skin lesions was also evaluated from the results in the EECT0 group treated with distilled water. The therapeutic efficacies of EECT 7.5, 25 and 75 mg/mL on the AD-like skin lesions were 1.7 (30.1%), 1.8 (31.4%) and 2.2 (38.5%) times higher than that of EECT 0 (17.8%) after 4 days (p = 0.0001), and 1.6 (63.6%), 1.7 (66.1%) and 1.3 (49.6%) times higher than that of EECT 0 (38.7%) after 14 days of EECT treatment (Figure 1). The anti-inflammatory efficacies of EECT 7.5, 25 and 75 mg/mL on serum IgE levels were also higher than those of EECT 0 (Figure 2). The anti-AD efficacy of EECT seemed to be more significant in the early stage (after 4 days) of EECT treatment than at the later stage of treatment.

AD appears to be associated with inflammatory immune dysregulation of the skin, impaired skin barrier func-tion, and IgE-mediated sensitization to food and environmental allergens such as microbial pathogens [29] [30]. Such immunologic disturbance is reflected in elevated serum IgE levels due to increased inflammatory cell in-filtration into the skin, which is type2 helper T-cell-dominated, and, according to the immune dysregulation hy-pothesis, the defective skin barrier is interpreted as a consequence of inflammation [2]. Regardless of how to explain disease progression, the acute eczematous lesions exhibit spongiosis, hyperkeratosis and parakeratosis, and the chronic lesions are characterized by acanthosis and perivascular infiltration of lymphocytes and mast cells, and by lichenification of the skin, infiltration of Th1 cells, and tissue remodeling with increased collagen deposition and dermal thickening [30]. From this point of view, the elevation of serum IgE levels in this NC/ Nga mouse AD model was related to the onset of AD-like skin lesion development [31] [32], and also similar to that reported in AD patients with IgE hyperproduction [33]. Therefore, topically applied EECT might be very effective in reducing systemic inflammatory reactions and diverse AD symptoms such as itch, edema, erythema/ hemorrhage, excoriation/erosion, and dryness/scaling in the early stage of AD treatment. This suggests that pa-tients with AD could obtain relief from the severe distress of AD symptoms more easily in the very highly in-duced AD state.

Many skin disorders like AD seem to be related to infiltration and activation of mast cells, resulting in skin inflammation [30] [34]. In the current study, total mast cell counts increased significantly after 21 days of sensi-tization (Figure 4). EECT treatment at 7.5, 25 and 75 mg/mL showed a tendency to suppress the mast cell pro-duction in the skin dermis layers of the head, neck and shoulder of the mice. This tendency to reduce dermal mast cells, specially degranulated mast cells, was significant in the EECT-treated groups (p = 0.0001), when compared to the EECT 0 group (Figure 4). The degranulated to granulated mast cell ratio (de-G/G) was greatly increased after AD induction, and the de-G/G ratio was lower after EECT treatment than after treatment with distilled water (data not shown) though the difference was not statistically significant (p = 0.162; normal (0.4070 ± 0.042) vs. EECT0 (6.914 ± 4.062) vs. EECT7.5 (2.049 ± 0.257) vs. EECT25 (1.308 ± 0.235) vs. EECT75 (2.1880 ± 0.357)). It has also been reported that stress-induced skin disorders due to infiltration and activation of mast cells in the skin dermis resulted in significant increases of granulated and degranulated mast cells in rats [34]-[36]. In allergic or stressed conditions, mast cells increase their IgE production [37], and degranulated mast cells that bind IgE increase [38] with a subsequent rise in histamine production, which generates severe itch and scratching of skin lesions [39]. Degranulated mast cells can initiate an acute inflammatory response and contribute to the progression of chronic diseases. Therefore, a decrease of mast cells, degranulated forms in particular, or of the deG/G ratios, in the skin is correlated with reductions of IgE and inflammatory responses, and could be a key to reducing the severity of AD-like skin lesions. Mast cells in the skin dermis of head and neck were considerably decreased by EECT 7.5, 25 and 75 mg/mL (Figure 4). This is of interest as the necks of AD patients were found to have higher number of mast cell profiles than any other region such as elbow, scalp and nates [3].

Y.-S. Park et al.

365

The current study has a few limitations. Thus, the considerable variability of one group resulted in limited sta-tistical power of the comparison with the other groups. It may have been caused by the small sample size of the groups. If the sample size had been larger, the anti-AD effect of EECT 7.5, 25 and 75 mg/mL might have been more significant at 14 days of EECT treatment than that of distilled water.

In spite of the above limitation, the current study’s strengths include the fact that the EECT was applied topi-cally to the AD-like skin lesions as an ointment. Most traditional oriental natural substances, such as mulberry tree extract and ginseng are orally administered. Secondly, NC/Nga mice develop AD-like skin lesions sponta-neously under normal conditions, and they are a suitable model for some aspects of human AD, with IgE hyper-production which is influenced by environmental factors, in part, due to interleukin-4 and -5 released by mast cells of the affected skin [31]. Therefore, the NC/Nga mouse model is useful for developing therapies for AD. In addition, it is very important to control and weaken the inflammation and dermatitis symptoms of AD, given that these unbearable AD symptoms are severer at night and prevalent in younger subjects. Because, AD is an in-tractable chronic disease there should be as much focus on its control as on its complete cure. From this point of view, EECT may be a possible solution to reduce AD symptoms while seeking a cure for the disease.

5. Conclusion Ethanol extract of C. tricuspidata stems (EECT) administered topically to an NC/Nga mouse AD model induced by D. farinae extract decreased serum IgE levels and degranulated mast cell counts in the dermis of the skin, and consequently improved the AD-like skin lesions. The anti-AD effect was especially significant when EECT 7.5 and 25 mg/mL were applied for 14 days, and the therapeutic effect was more obvious in the early stage of EECT treatment when AD was strongly induced than later in the treatment.

References [1] Leung, D.Y.M. (1999) Pathogenesis of Atopic Dermatitis. Journal of Allergy and Clinical Immunology, 104, S99-S108.

http://dx.doi.org/10.1016/S0091-6749(99)70051-5 [2] Joo, S.S., Kim, S.G., Choi, S.E., Kim, Y.-B., Park, H.Y., Seo, S.J., Choi, Y.W., Lee, M.W. and Lee, D.I. (2009) Sup-

pression of T Cell Activation by Hirsutenone, Isolated from the Bark of Alnus japonica, and Its Therapeutic Advan-tages for Atopic Dermatitis. European Journal of Pharmacology, 614, 98-105. http://dx.doi.org/10.1016/j.ejphar.2009.04.047

[3] Damsgaard, T.E., Olesen, A.B., Sørensen, F.B., Thestrup-Pedersen, K. and Schiøtz, P.O. (1997) Mast Cells and Atopic Dermatitis. Stereological Quantification of Mast Cells in Atopic Dermatitis and Normal Human Skin. Archives of Der- matological Research, 289, 256-260. http://dx.doi.org/10.1007/s004030050189

[4] Cho, E.J., Yokozawa, T., Rhyu, D.Y., Kim, S.C., Shibahara, N. and Park, J.C. (2003) Study on the Inhibitory Effects of Korean Medicinal Plants and Their Main Compounds on the 1,1-Diphenyl-2-Picrylhydrazyl Radical. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology, 10, 544-551. http://dx.doi.org/10.1078/094471103322331520

[5] Song, M.J. and Kim, H. (2011) Ethnomedicinal Application of Plants in the Western Plain Region of North Jeolla Province in Korea. Journal of Ethnopharmacology, 137, 167-175. http://dx.doi.org/10.1016/j.jep.2011.05.001

[6] Shi, L., Fu, Y.L. and Chen, K.S. (2007) A Novel Water-Soluble α-(1→4)-Glucan from the Root of Cudrania tricuspi-data. Fitoterapia, 78, 298-301. http://dx.doi.org/10.1016/j.fitote.2007.03.007

[7] Kang, B., Liu, S., Cai, D. and Wen, Y. (2006) Species Composition and Correlation of Understory Woody Plants in Chinese Fir Plantation in the Lower Subtropical Area. Frontiers of Biology in China, 1, 423-429. http://dx.doi.org/10.1007/s11515-006-0057-0

[8] Tian, Y.H., Kim, H.C., Cui, J.M. and Kim, Y.C. (2005) Hepatoprotective Constituents of Cudrania tricuspidata. Arc-hives of Pharmacal Research, 28, 44-48. http://dx.doi.org/10.1007/BF02975134

[9] An, R.B., Sohn, D.H. and Kim, Y.C. (2006) Hepatoprotective Compounds of the Roots of Cudrania tricuspidata on Tacrine-Induced Cytotoxicity in Hep G2 Cells. Biological &Pharmaceutical Bulletin, 29, 838-840. http://dx.doi.org/10.1248/bpb.29.838

[10] Kim, O.K., Ho, J.N., Nam, D.E., Jun, W., Hwang, K.T., Kang, J.E., Chae, O.S. and Lee, J. (2012) Hepatoprotective Effect of Curdrania tricuspidata Extracts against Oxidative Damage. Journal of the Korean Society of Food Science and Nutrition, 41, 7-13. http://dx.doi.org/10.3746/jkfn.2012.41.1.007

[11] Kang, D.G., Hur, T.Y., Lee, G.M., Oh, H., Kwon, T.O., Sohn, E.J. and Lee, H.S. (2002) Effects of Cudrania tricuspi-data Water Extract on Blood Pressure and Renal Functions in NO-Dependent Hypertension. Life Sciences, 70, 2599-

Y.-S. Park et al.

366

2609. http://dx.doi.org/10.1016/S0024-3205(02)01547-3 [12] Park, J.H., Lee, K.W., Sung, K.S., Kim, S.S., Cho, K.D., Lee, B.H. and Han, C.K. (2012) Effect of Diets with Mulber-

ry Leaf and Cudrania tricuspidata Leaf Powder Supplements on Blood Glucose-Related Biomarkers in Streptozotocin- Induced Diabetic Rats. Journal of the Korean Society of Food Science and Nutrition, 41, 766-773. http://dx.doi.org/10.3746/jkfn.2012.41.6.766

[13] Park, W.Y., Ro, J.S. and Lee, K.S. (2001) Hypoglycemic Effect of Cudrania tricuspidata Root Bark. Korean Journal of Pharmacognosy, 32, 248-252.

[14] Oh, P.S., Lee, H.J. and Lim, K.T. (2009) Inhibitory Effect of Glycoprotein Isolated from Cudrania tricuspidata Bureau on Histamine Release and COX-2 Activity in RBL-2H3 Cells. Korean Journal of Food Science and Technology, 41, 405-412.

[15] Park, B.H., Back, K.Y., Lee, S.I. and Kim, S.D. (2008) Quality and Antioxidative Characteristics of Cudrania tricus-pidata Leaves Tea. Korean Journal of Food Preservation, 15, 461-468.

[16] Chon, I.J., Lee, S.W., Cha, J.H., Han, J.H. and Whang, W.K. (2005) Anti-Oxidant Compounds of Cudrania tricuspi-data Leaves. Yakhak Hoeji, 49, 416-421.

[17] Jeong, C.H., Choi, G.N., Kim, J.H., Kwak, J.H., Heo, H.J., Shim, K.H., Cho, B.R., Bae, Y.I. and Choi, J.S. (2009) In Vitro Antioxidative Activities and Phenolic Composition of Hot Water Extract from Different Parts of Cudrania tri-cuspidata. Preventive Nutrition and Food Science, 14, 283-289. http://dx.doi.org/10.3746/jfn.2009.14.4.283

[18] Han, X.H., Hong, S.S., Jin, Q., Li, D., Kim, H.-K., Lee, J., Kwon, S.H., Lee, D., Lee, C.-K., Lee, M.K. and Hwang, B.Y. (2009) Prenylated and Benzylated Flavonoids from the Fruits of Cudrania tricuspidata. Journal of Natural Products, 72, 164-167. http://dx.doi.org/10.1021/np800418j

[19] Kim, Y.C., Hur, J., Sohn, D.H. and Kim, H.S. (2008) Antibacterial Compounds of the Root Barks of Cudrania tricus-pidata. Korean Journal of Pharmacognosy, 39, 246-248.

[20] Kim, S.H., Kim, N.J., Choi, J.S. and Park, J.C. (1993) Determination of Flavonoid by HPLC and Biological Activities from the Leaves of Cudrania tricuspidata Bureau. Journal of the Korean Society of Food Science and Nutrition, 22, 68-72.

[21] Park, J.C., Young, H.S. and Choi, J.S. (1992) Constituents of Cudrania tricuspidata in Korea. Yakhak Hoeji, 36, 40-45. [22] Lee, H., Ha, H., Lee, J.K., Seo, C.S., Lee, N.H., Jung, D.Y., Park, S.J. and Shin, H.K. (2012) The Fruits of Cudrania

tricuspidata Suppress Development of Atopic Dermatitis in NC/Nga Mice. Phytotherapy Research, 26, 594-599. http://dx.doi.org/10.1002/ptr.3577

[23] Yamamoto, M., Haruna, T., Yasui, K., Takahashi, H., Iduhara, M., Takaki, S., Deguchi, M. and Arimura, A. (2007) A Novel Atopic Dermatitis Model Induced by Topical Application with Dermatophagoides farinae Extract in NC/Nga Mice. Allergology International, 56, 139-148. http://dx.doi.org/10.2332/allergolint.O-06-458

[24] Leung, D.Y., Hirsch, R.L., Schneider, L., Moody, C., Takaoka, R., Li, S.H., Meyerson, L.A., Mariam, S.G., Goldstein, G. and Hanifin, J.M. (1990) Thymopentin Therapy Reduces the Clinical Severity of Atopic Dermatitis. The Journal of Allergy and Clinical Immunology, 85, 927-933. http://dx.doi.org/10.1016/0091-6749(90)90079-J

[25] Yamaguchi, T., Maekawa, T., Nishikawa, Y., Nojima, H., Kaneko, M., Kawakita, T., Miyamoto, T. and Kuraishi, Y. (2001) Characterization of Itch-Associated Responses of NC Mice with Mite-Induced Chronic Dermatitis. Journal of Dermatological Science, 25, 20-28. http://dx.doi.org/10.1016/S0923-1811(00)00099-2

[26] Administration KFD (2010) The Guideline for Effect Tests of Herbal Medicines: Atopic Dermatitis. In: Department of Bio-Herbal Medicine KFDA, Ed., Korean Food and Drug Administration, Seoul, 1-14.

[27] Damsgaard, T.E., Olesen, A.B., Sørensen, F.B., Thestrup-Pedersen, K. and Schiøtz, P.O. (1997) Mast Cells and Atopic Dermatitis. Stereological Quantification of Mast Cells in Atopic Dermatitis and Normal Human Skin. Archives of Dermatological Research, 289, 256-260. http://dx.doi.org/10.1007/s004030050189

[28] Internet Pathology Laboratory (2011) Mast Cells—O TOLUIDINE Blue. http://www-medlib.med.utah.edu/WebPath/webpath.html

[29] Leung, D.Y.M. (2006) New Insights into the Complex Gene-Environment Interactions Evolving into Atopic Dermatitis. The Journal of Allergy and Clinical Immunology, 118, 37-39. http://dx.doi.org/10.1016/j.jaci.2006.04.045

[30] Kawakami, T., Ando, T., Kimura, M., Wilson, B.S. and Kawakami, Y. (2009) Mast Cells in Atopic Dermatitis. Cur-rent Opinion in Immunology, 21, 666-678. http://dx.doi.org/10.1016/j.coi.2009.09.006

[31] Matsuda, H., Watanabe, N., Geba, G.P., Sperl, J., Tsudzuki, M., Hiroi, J., Matsumoto, M., Ushio, H., Saito, S., Aske-nase, P.W. and Ra, C. (1997) Development of Atopic Dermatitis-Like Skin Lesion with IgE Hyperproduction in NC/ Nga Mice. International Immunology, 9, 461-466. http://dx.doi.org/10.1093/intimm/9.3.461

[32] Park, S., Lee, J.B. and Kang, S. (2012) Topical Application of Chrysanthemum indicum L. Attenuates the Develop-ment of Atopic Dermatitis-Like Skin Lesions by Suppressing Serum IgE Levels, IFN-gamma, and IL-4 in Nc/Nga

Y.-S. Park et al.

367

Mice. Evidence-Based Complementary and Alternative Medicine, 2012, Article ID: 821967. http://dx.doi.org/10.1155/2012/821967

[33] Van Bever, H.P. (1992) Recent Advances in the Pathogenesis of Atopic Dermatitis. European Journal of Pediatrics, 151, 870-873. http://dx.doi.org/10.1007/BF01954120

[34] Cikler, E., Ersoy, Y., Cetinel, S. and Ercan, F. (2009) The Leukotriene d4 Receptor Antagonist, Montelukast, Inhibits Mast Cell Degranulation in the Dermis Induced by Water Avoidance Stress. Acta Histochemica, 111, 112-118. http://dx.doi.org/10.1016/j.acthis.2008.04.006

[35] Seo, Y.M. and Jeong, S.H. (2015) Effects of Blending Oil of Lavender and Thyme on Oxidative Stress, Immunity, and Skin Condition in Atopic Dermatitis Induced Mice. Journal of Korean Academy of Nursing, 45, 367-377. http://dx.doi.org/10.4040/jkan.2015.45.3.367

[36] Cikler, E., Ercan, F., Cetinel, S., Contuk, G. and Sener, G. (2009) The Protective Effects of Melatonin against Water Avoidance Stress-Induced Mast Cell Degranulation in Dermis. Acta Histochemica, 106, 467-475. http://dx.doi.org/10.1016/j.acthis.2004.10.001

[37] Elias, P.M. and Schmuth, M. (2009) Abnormal Skin Barrier in the Etiopathogenesis of Atopic Dermatitis. Current Opinion in Allergy & Clinical Immunology, 9, 437-446. http://dx.doi.org/10.1097/ACI.0b013e32832e7d36

[38] Yamashita, H., Tasaki, D., Makino, T., Matsuoka, K., Nose, M., Inagaki, N. and Mizukami, H. (2009) The Role of IgE and Repeated Challenge in the Induction of Persistent Increases in Scratching Behavior in a Mouse Model of Allergic Dermatitis. European Journal of Pharmacology, 605, 153-157. http://dx.doi.org/10.1016/j.ejphar.2009.01.006

[39] Cowden, J.M., Zhang, M., Dunford, P.J. and Thurmond, R.L. (2010) The Histamine H4 Receptor Mediates Inflamma-tion and Pruritus in Th2-Dependent Dermal Inflammation. Journal of Investigative Dermatology, 130, 1023-1033. http://dx.doi.org/10.1038/jid.2009.358

Submit or recommend next manuscript to SCIRP and we will provide best service for you: Accepting pre-submission inquiries through Email, Facebook, LinkedIn, Twitter, etc. A wide selection of journals (inclusive of 9 subjects, more than 200 journals) Providing 24-hour high-quality service User-friendly online submission system Fair and swift peer-review system Efficient typesetting and proofreading procedure Display of the result of downloads and visits, as well as the number of cited articles Maximum dissemination of your research work

Submit your manuscript at: http://papersubmission.scirp.org/